While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...

Anthropic’s Cowork brings Claude Code–style AI agents to the desktop, letting Claude access and manage local files and browse ...

Recursion Pharmaceuticals has reported updated data from its ELUCIDATE & TUPELO trials, but the stock has failed to mount a ...

Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to company-specific news or drug announcements, but rather due to actions taken by artificial intelligence ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $4.70, marking a -3.29% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.01%.

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best High Volume Penny Stocks to Buy. On December 17, Priyanka Grover from J.P. Morgan upgraded Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ...